[go: up one dir, main page]

MX2009010984A - Fused ring heterocycle kinase modulators. - Google Patents

Fused ring heterocycle kinase modulators.

Info

Publication number
MX2009010984A
MX2009010984A MX2009010984A MX2009010984A MX2009010984A MX 2009010984 A MX2009010984 A MX 2009010984A MX 2009010984 A MX2009010984 A MX 2009010984A MX 2009010984 A MX2009010984 A MX 2009010984A MX 2009010984 A MX2009010984 A MX 2009010984A
Authority
MX
Mexico
Prior art keywords
fused ring
modulators
ring heterocycle
kinase modulators
heterocycle kinase
Prior art date
Application number
MX2009010984A
Other languages
Spanish (es)
Inventor
Chixu Chen
Brian Eastman
Andreas Gosberg
Stefan N Gradl
Gavin Hirst
Stephanie Hopkins
Khanh Thi Tuong Nguyen
Richard Pracitto
Paul A Sprengeler
Rou W Steensma
Original Assignee
Sgx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgx Pharmaceuticals Inc filed Critical Sgx Pharmaceuticals Inc
Publication of MX2009010984A publication Critical patent/MX2009010984A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.
MX2009010984A 2007-04-10 2008-04-10 Fused ring heterocycle kinase modulators. MX2009010984A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91106007P 2007-04-10 2007-04-10
PCT/US2008/059962 WO2008124848A1 (en) 2007-04-10 2008-04-10 Fused ring heterocycle kinase modulators

Publications (1)

Publication Number Publication Date
MX2009010984A true MX2009010984A (en) 2010-01-15

Family

ID=39831449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010984A MX2009010984A (en) 2007-04-10 2008-04-10 Fused ring heterocycle kinase modulators.

Country Status (12)

Country Link
US (1) US8242280B2 (en)
EP (1) EP2078020A4 (en)
JP (1) JP2010524858A (en)
KR (1) KR20100066419A (en)
CN (1) CN101679436A (en)
AU (1) AU2008237019A1 (en)
BR (1) BRPI0809500A2 (en)
CA (1) CA2683398A1 (en)
EA (1) EA200901157A1 (en)
MX (1) MX2009010984A (en)
NO (1) NO20093009L (en)
WO (1) WO2008124848A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744498C (en) 2008-11-25 2017-10-24 University Of Rochester Mlk inhibitors and methods of use
JOP20190230A1 (en) 2009-01-15 2017-06-16 Incyte Corp Methods for repairing JAK inhibitors and related intermediates
CN102595900B (en) 2009-08-10 2015-07-15 萨穆梅德有限公司 Indazole Inhibitors of the Wnt Signaling Pathway and Their Therapeutic Uses
EP2515655B1 (en) 2009-12-21 2015-08-05 Samumed, LLC 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof
CU24167B1 (en) 2009-12-31 2016-03-31 Hutchison Medipharma Ltd DERIVATIVES OF REPLACED TRIAZOLOPIRAZINS AS INHIBITORS OF THE C-MET OR HGF RECEPTOR TO TREAT CANCER
AU2011258465B2 (en) 2010-05-24 2016-12-15 University Of Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CN104628603B (en) * 2010-07-02 2017-08-15 比皮艾思药物研发有限公司 Carbanilate compound and the muscle relaxant containing carbanilate compound
CN103282346B (en) 2011-01-13 2014-11-19 比皮艾思药物研发有限公司 Process for preparation of phenyl carbamate derivatives
AU2012308570B2 (en) 2011-09-14 2016-11-10 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
DE102011119127A1 (en) 2011-11-22 2013-05-23 Merck Patent Gmbh 3-Cyanaryl-1H-pyrrolo [2,3-b] pyridine derivatives
BR112014015482A8 (en) 2011-12-27 2017-07-04 Bio Pharm Solutions Co Ltd phenyl carbamate compounds for use in the alleviation or treatment of pain and neuropathic pain
AU2013203824A1 (en) 2012-03-16 2013-10-03 Purdue Pharma L.P. Substituted pyridines and pryimidines as sodium channel blockers
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
SG10201710585UA (en) 2012-05-04 2018-02-27 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
EP2925319B1 (en) 2012-11-30 2019-01-09 University Of Rochester Mixed lineage kinase inhibitors for hiv/aids therapies
CA2897400A1 (en) 2013-01-08 2014-07-17 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
KR20160004260A (en) * 2013-03-12 2016-01-12 (주)바이오팜솔루션즈 Phenyl carbamate compound and a composition for neuroprotection comprising the same
CN105228604A (en) 2013-03-12 2016-01-06 比皮艾思药物研发有限公司 Phenylcarbamate compounds for preventing or treating epilepsy and epilepsy-related syndromes in children
KR20150135460A (en) 2013-03-28 2015-12-02 우베 고산 가부시키가이샤 Substituted biaryl compound
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
AU2016209046A1 (en) * 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10392383B2 (en) 2015-08-03 2019-08-27 Samumed, Llc 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024025A1 (en) 2015-08-03 2017-02-09 Sunil Kumar Kc 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023975A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017023986A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
CN108472290A (en) 2015-11-06 2018-08-31 萨穆梅德有限公司 treat osteoarthritis
AR108325A1 (en) 2016-04-27 2018-08-08 Samumed Llc ISOQUINOLIN-3-IL CARBOXAMIDS AND PREPARATION AND USE OF THE SAME
PT3464285T (en) 2016-06-01 2022-12-20 Biosplice Therapeutics Inc Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
RU2770613C2 (en) 2016-10-21 2022-04-19 СЭМЬЮМЕД, ЭлЭлСи Methods for using indazole-3-carboxamides and their use as inhibitors of wnt/b-catenin signal path
WO2018085865A1 (en) 2016-11-07 2018-05-11 Samumed, Llc Single-dose, ready-to-use injectable formulations
JP7050165B2 (en) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Substituted pyrrolidine compounds as HBV replication inhibitors
CN112409207B (en) * 2019-08-22 2022-11-22 新发药业有限公司 Preparation method of dimoxystrobin
CN118745146B (en) * 2024-06-24 2025-09-23 上海坦泰生物科技有限公司 Preparation method of 5-fluoro-2-hydrazinopyridine dihydrochloride

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604091A (en) 1984-03-01 1997-02-18 Microgenics Corporation Methods for protein binding enzyme complementation
GB9918035D0 (en) 1999-07-30 1999-09-29 Novartis Ag Organic compounds
MXPA03005432A (en) 2000-12-22 2003-09-10 Wyeth Corp Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands.
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2006501217A (en) 2002-08-12 2006-01-12 スージェン・インコーポレーテッド 3-Pyrrolyl-pyridopyrazole and 3-pyrrolyl-indazole as novel kinase inhibitors
US20040142864A1 (en) 2002-09-16 2004-07-22 Plexxikon, Inc. Crystal structure of PIM-1 kinase
US7432375B2 (en) * 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
TWI339206B (en) * 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
EP2332940B1 (en) 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
KR20070053236A (en) * 2004-07-27 2007-05-23 에스지엑스 파마슈티컬스, 인코포레이티드 Fused Ring Heterocycle Kinase Modulators
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
AU2005269386A1 (en) * 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
JP4954086B2 (en) * 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 1H-pyrrolo [2,3-B] pyridine
US20080300267A1 (en) 2005-05-16 2008-12-04 Barun Okram Compounds and Compositions as Protein Kinase Inhibitors
CL2008001540A1 (en) * 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compounds derived from pyrrolopyridines and pyrazolopyridines; pharmaceutical composition; and use in the treatment of cancer.
DE102007028515A1 (en) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives

Also Published As

Publication number Publication date
EP2078020A1 (en) 2009-07-15
NO20093009L (en) 2009-12-17
US20080261921A1 (en) 2008-10-23
AU2008237019A1 (en) 2008-10-16
CN101679436A (en) 2010-03-24
BRPI0809500A2 (en) 2014-09-23
KR20100066419A (en) 2010-06-17
WO2008124848A1 (en) 2008-10-16
US8242280B2 (en) 2012-08-14
JP2010524858A (en) 2010-07-22
CA2683398A1 (en) 2008-10-16
EP2078020A4 (en) 2011-10-19
EA200901157A1 (en) 2010-04-30

Similar Documents

Publication Publication Date Title
MX2009010984A (en) Fused ring heterocycle kinase modulators.
MX2009012623A (en) Heterocyclic kinase modulators.
TNSN07028A1 (en) Fused ring heterocycle kinase modulators
MY162604A (en) Heterocyclic compounds and uses thereof
TW200745109A (en) Pyrrolo-pyridine kinase modulators
IN2012DN00943A (en)
PH12015501955B1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
WO2008124849A3 (en) Pyrrolo-pyridine kinase modulators
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
TW200833692A (en) Triazolopyridazine protein kinase modulators
MX2009009491A (en) Compounds and compositions as modulators of gpr119 activity.
MX2009006704A (en) New compounds.
EA201290209A1 (en) NEW MODULATORS OF KENAZES BENZIPIRANE
PH12013502240B1 (en) Novel compounds as modulators of protein kinase
EA201170349A1 (en) MIF MODULATORS
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
MX2009006706A (en) Bicyclic heterocyclic compounds as fgfr inhibitors.
MX2012004078A (en) Compounds and compositions as modulators of gpr119 activity.
MX2012001974A (en) Biaryl compounds and methods of use thereof.
MX2014000964A (en) Substituted heterocyclic aza derivatives.
GEAP201814515A (en) 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139
GEP20156318B (en) Heteroaryl derivatives as alpha7 nachr modulators
MX2010006206A (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases.
UA115523C2 (en) Solid state forms of macrocyclic kinase inhibitors
MX2013002446A (en) Substituted tetrahydropyrrolopyrazine derivatives.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal